News Headlines Article

FDA questions Amgen drug for prostate cancer
USA Today

Scientists for the Food and Drug Administration say that an Amgen drug slowed the spread of cancer to the bone in men with hard-to-treat prostate cancer, though the drug did not extend life and carried significant side effects. The Food and Drug Administration will ask a panel of outside experts on Wednesday whether the benefits of Amgen’s Xgeva outweigh its risks, which included bone disease in about 5 percent of patients taking the drug. The agency posted its review of the drug online Monday morning ahead of the meeting.